The BBX Knockout A-549 Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma cell line, in which the BBX gene has been disrupted to generate a loss-of-function model. This polyclonal format provides a heterogeneous pool of cells with targeted gene disruption, enabling robust and reproducible investigation of BBX-dependent cellular processes without the selective pressure of single-cell cloning. The cells serve as a powerful tool for studying the transcriptional regulatory mechanisms governed by BBX in cancer biology contexts.
A-549 cells are an established epithelial cell line originally isolated from a human lung carcinoma explant, widely employed as a model system for non-small cell lung adenocarcinoma. Their well-characterized growth properties, genetic landscape, and responsiveness to chemotherapeutic agents make them a standard host for gene-editing studies aimed at dissecting molecular pathways underlying lung cancer pathogenesis and drug sensitivity. This host background is particularly relevant for exploring the role of transcription factors that modulate tumor cell proliferation, survival, and metastatic potential.
BBX (Bobby Sox homolog) is an HMG-box transcription factor that intricately integrates signals from multiple oncogenic pathways. BBX directly interacts with the Notch intracellular domain (NICD) and the co-activator MAML1, thereby regulating the expression of canonical Notch target genes such as HES1 and HEY1. Additionally, BBX associates with co-repressor complexes containing HDAC1 and SIN3A to modulate chromatin status at promoter regions of critical cell cycle and apoptosis regulators, including MYC and CCND1. This dual functionality positions BBX as a node that fine-tunes transcriptional outputs in response to upstream cues from NOTCH receptors, TP53, and Wnt ligands, ultimately influencing downstream effectors like CDKN1A (p21) and BCL2 family members.
In the context of A-549 lung adenocarcinoma cells, loss of BBX function provides a physiologically relevant platform to dissect its contributions to oncogenic processes. Given that aberrant Notch and Wnt/??-catenin signaling are frequently implicated in lung cancer progression, this knockout model allows researchers to delineate how BBX-mediated crosstalk between these pathways affects cell cycle progression, apoptosis, and cellular senescence. Moreover, the interplay between BBX and TP53-dependent responses can be examined to understand how transcription factor networks govern therapeutic resistance in solid tumors.
Typical applications encompass a wide range of molecular and cellular assays. RNA-seq can reveal global transcriptomic changes upon BBX disruption, while ChIP-qPCR enables mapping of BBX occupancy at target loci such as the MYC and CCND1 promoters. Functional studies include MTT or BrdU proliferation assays, Annexin V/PI apoptosis assays, and transwell migration/invasion analyses. Notch and Wnt pathway activities can be quantitatively assessed using luciferase-based reporter assays. Drug sensitivity profiling with chemotherapeutic agents further supports validation of BBX as a potential therapeutic target in lung adenocarcinoma. For ordering information or technical support, please contact Ascent Research.
